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Abstract 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are the 
primary conduits of excitatory synaptic transmission. AMPARs are predominantly 
Ca2+-impermeable in the matured excitatory synapse, except under certain 
circumstances. Growing evidence implicates the Ca2+ permeability of AMPARs in the 
regulation of long-term synaptic plasticity and in the pathophysiology of several 
neurological disorders. Therefore, the Ca2+ conductance of AMPARs may have both 
physiological and pathological roles at synapses. However, our understanding of the 
role of Ca2+ permeable AMPARs (CP-AMPARs) in Alzheimer’s disease is limited. 
Here we discuss insights into the potential CP-AMPAR mediated pathophysiology of 
Alzheimer’s disease, including: 1. Ca2+-mediated aberrant regulation of synapse 
weakening mechanisms, and 2. neuronal network dysfunction in the brain. 
Consideration of CP-AMPARs as primary drivers of pathophysiology could help in 
understanding synaptopathologies, and highlights the potential of CP-AMPARs as 
therapeutic targets in Alzheimer’s disease. 
 
 
It has become increasingly evident that in certain pathological states, AMPAR 
expression is compromised, resulting in alterations to synaptic function. CP-AMPARs 
in particular have well-established roles in epilepsy (Grooms et al., 2000, 
Rajasekaran et al., 2012, Malkin et al., 2016), ischaemia (Kwak and Weiss, 2006), 
traumatic brain injury (Spaethling et al., 2008),  and illicit substance addiction and 
withdrawal (Pistillo et al., 2016, Wolf, 2016). Indeed, the contribution of CP-AMPARs 
to these disease etiologies has been thoroughly reviewed (Tanaka et al., 2000, Liu 
and Zukin, 2007, Henley and Wilkinson, 2016) and the potential for targeting 
AMPARs as a therapeutic strategy continues to be explored (Chang et al., 2012, 
Franco et al., 2013, Zaccara and Schmidt, 2016). In addition to these diseases, it has 
been postulated that CP-AMPARs might also contribute to progressive 
neurodegeneration (Weiss and Sensi, 2000, Kwak and Weiss, 2006). However, until 
recently, there has been limited evidence to support this claim. Thus, this review will 
discuss recent evidence implicating CP-AMPARs in Alzheimer’s Disease (AD), and 
describe how targeting AMPARs may offer a potential therapeutic strategy in treating 
AD patients. 
 
1. Ca2+-permeable AMPA receptors: structure, function and expression 
α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are 
ionotropic receptors, formed by the tetrameric assembly of GluA1-4 subunits, and are 
widely expressed throughout the central nervous system (Hollmann and Heinemann, 
1994). AMPARs are highly dynamic complexes, being able to transition between 
different subunit assembles depending on the synaptic environment (Schwenk et al., 
2014, Herguedas et al., 2016). In the adult hippocampus, AMPARs are typically 
composed of a combination of GluA1 and GluA2, or GluA2 and GluA3 subunits 
(Wenthold et al., 1996). The AMPAR subunits themselves have four distinct domains: 
an N-terminal extracellular domain; a ligand binding domain (composed of two 
extracellular polypeptide sections, termed S1 and S2 (Keinanen et al., 1990, Stern-
Bach et al., 1994); a membrane-localised channel domain (formed by three 
transmembrane α-helices and a channel pore loop, termed M1, M2, M3 and M4); 
and an intracellular C-terminal domain (Figure 1). 
  
The functional properties of AMPARs depend on the composition of its subunits. For 
instance, inclusion of the GluA2 subunit in a receptor confers Ca2+ impermeability 
and these are the major species of receptor found in glutamatergic neurons 
(Wenthold et al., 1996). The impermeability to Ca2+ is conferred by editing of the Q/R 
site of GluA2 pre-mRNA. Here, a glutamine (Q) codon (which lies within the channel-
forming M2 re-entrant membrane loop region) is modified into an arginine (R) codon 
(Sommer et al., 1991, Burnashev et al., 1992). However, AMPARs can be Ca2+ 
permeable in certain circumstances; (1) in the instances where they contain unedited 
GluA2(Q) subunits, or (2) when they are formed without the inclusion of the GluA2 
subunit. GluA2-lacking AMPARs, which are often homomeric for the GluA1 subunit, 
are termed Ca2+-permeable AMPARs (CP-AMPARs). CP-AMPARs are known to 
have greater single channel conductance than GluA2-containing AMPARs (Swanson 
et al., 1997), though less than N-methyl-D-aspartate receptors (NMDARs) 
(Dingledine et al., 1999). Additionally, CP-AMPARs have faster desensitization 
constants than GluA2-containing receptors (Traynelis et al., 2010) The majority of 
CP-AMPARs display a inwardly rectifying current-voltage relationship (though see 
Gilbertson et al., 1991), whereby the receptors do not permit the passage of current 
at depolarising membrane potentials, due to channel pore blockade by intracellular 
polyamines (Bowie and Mayer, 1995, Donevan and Rogawski, 1995, Guerra et al., 
2016); Figure 2A, B). This change in rectification properties conferred by 
endogenous intracellular polyamines is, however, subject to regulation by the 
AMPAR auxiliary subunit stargazin (Soto et al., 2007). Stargazin reduces the 
sensitivity of CP-AMPARs to polyamine block, as well as increasing single-channel 
conductance and slowing deactivation of receptors, altogether increasing the influx of 
Ca2+. This regulation of channel properties by stargazin may increase the functional 
diversity of CP-AMPARs, with populations of CP-AMPARs in regions where stargazin 
is not expressed displaying altered functional characteristics. The wide-ranging 
effects that external and internal polyamines have on AMPAR channel conductance, 
and contrasting data obtained from bi-polar retinal cells, has led some to question 
whether GluA2-containing AMPARs can actually display Ca2+-permeable 
characteristics (Bowie, 2012). Thus, it is highly evident that further investigation is 
required to substantiate the exact composition of the different populations of 
AMPARs. 
 
Expression of CP-AMPARs is evident during the early developmental stages of the 
hippocampus, compared to just a small fraction of CP-AMPARs present in mature 
hippocampal neurons (Wenthold et al., 1996, Rozov et al., 2012). This is in part due 
to the presence of unedited forms of GluA2 mRNA at embryonic stages, which later 
become almost entirely obsolete as the brain reaches maturity (Burnashev et al., 
1992, Kawahara et al., 2003). Coupled with a higher ratio of GluA1, GluA3, and 
GluA4 to GluA2 subunits, CP-AMPARs are known to be relatively prevalent in the 
hippocampus during the first few postnatal weeks (Pellegrini-Giampietro et al., 1992, 
Ho et al., 2007). However, a subsequent increase in edited GluA2 subunit expression 
can be seen after approximately 1-3 weeks of postnatal development (Pellegrini-
Giampietro et al., 1992, Pickard et al., 2000, Ho et al., 2007, Blair et al., 2013). A 
similar profile is found in other brain regions, where low GluA2 abundance in early 
developmental stages results in CP-AMPAR expression in neonatal neurons of the 
cortex, striatum and cerebellum, which gradually declines after a short developmental 
time window (Pellegrini-Giampietro et al., 1992, Kumar et al., 2002, Shin et al., 2007, 
Miyazaki et al., 2012). Other findings have shown that CP-AMPARs emerge at later 
time points in certain cell-types, replacing Ca2+-impermeable AMPARs in fast spiking 
interneurons of the prefrontal cortex during adolescence (Wang and Gao, 2010). 
Thus, the expression of CP-AMPAR is tightly regulated and linked to developmental 
stages, brain regions and distinct cell-types. 
 
2. Physiological roles of Ca2+-permeable AMPA receptors at the synapse  
Though limited in their expression in the mature synapse, CP-AMPARs are 
nevertheless thought to play important roles in the physiological function of neurons. 
AMPARs are pivotal in both the induction and expression of plasticity events that 
occur during synaptic stimulation (Henley and Wilkinson, 2016). The insertion of 
AMPARs at the synapse is an underlying molecular mechanism of long-term 
potentiation (LTP), a form of synaptic plasticity widely considered to be a correlate of 
learning and memory at the molecular level (Bliss and Collingridge, 1993). Whilst it 
was initially thought that only heteromeric assemblies of AMPARs containing both 
GluA1 and GluA2 subunits were trafficked to the synaptic membrane of CA1 
pyramidal neurons during synaptic stimulation, later studies have shown that 
expression of LTP requires the insertion of CP-AMPARs under certain circumstances, 
but that their expression is transient (< 25 min) in nature (Jia et al., 1996, Plant et al., 
2006, Jaafari et al., 2012, Park et al., 2016). It is however, debatable whether CP-
AMPARs are expressed during LTP induction (Adesnik and Nicoll, 2007, Gray et al., 
2007). Whilst these two studies bring in to question the importance of CP-AMPARs in 
the induction of synaptic plasticity, a possible explanation for these contradictory 
results may be related to the age of animal and experimental protocol. This was 
observed in a recent study, where LTP was blocked by IEM-1460 - a voltage-
dependent AMPAR open channel blocker selective for CP-AMPARs (Schlesinger et 
al., 2005) - in animals around 2 weeks of age (Sanderson et al., 2016). In contrast, 
LTP in animals closer to 3 weeks of age was insensitive to IEM-1460 treatment, 
illustrating the small time frame in which CP-AMPARs may contribute to synaptic 
plasticity. Here, we will not cover this debate further since it is beyond scope of this 
review, however it is clear that further work is required to fully understand the specific 
circumstances where CP-AMPARs are pivotal for plasticity induction. 
 
We have recently shown that in addition to possible roles in the induction of LTP per 
se, CP-AMPARs might also confer metaplastic properties to hippocampal neurons. 
We reported that acute stress or brief application of the GR agonist dexamethasone 
(DEX) results in a long-lasting increase in synaptic potentiation, which is mediated 
through the insertion of CP-AMPARs at the synaptic membrane (Whitehead et al., 
2013) (Figure 3). We showed that, whilst this stress-induced increase in LTP was, in 
part, mediated through activation of NMDARs, a portion of synaptic potentiation was 
found to be sensitive to treatment with IEM-1460, indicating the involvement of CP-
AMPARs. Moreover, acute stress resulted in an inwardly rectifying current/voltage 
(I/V) relationship, which is indicative of increased CP-AMPAR surface expression. 
We also found that the expression of CP-AMPARs required the protein kinase A 
(PKA)-mediated phosphorylation of the GluA1 serine 845 residue (S845), a known 
mechanism regulating CP-AMPAR synaptic expression (He et al., 2009). Consistent 
with our findings, a recent report has noted that acute footshock stress results in the 
rapid upregulation of S845 GluA1 phosphorylation, suggestive of the increased 
incorporation/stabilization of GluA1-containing AMPARs (Bonini et al., 2016). Further, 
phosphorylation of GluA1 at the serine 831 residue (S831) was found to occur under 
certain circumstances following acute swim stress (Fumagalli et al., 2012), which 
robustly increases single channel conductance (Kristensen et al., 2011). Taken 
together, these results suggest that CP-AMPARs can rapidly respond to 
environmental stimuli in order to regulate synaptic transmission and function. 
Interestingly, whilst the findings of CP-AMPARs in acute stress might suggest a role 
in enhancing memory or learning, conversely, CP-AMPARs have also been shown to 
also be important in memory erasure (Clem and Huganir, 2010). During the 
consolidation period following fear memory conditioning, expression of CP-AMPARs 
in the amygdala was found to be increased, which resulted in a greater magnitude of 
the long-term depression (LTD) form of synaptic plasticity and increased chance of 
memory extinction. Thus, it appears that CP-AMPARs can regulate both forms of 
synaptic activity – LTP and LTD. For example, it was shown that CP-AMPARs are 
recruited to the synaptic membrane during LTD induction, through activation of PKA 
anchored to a kinase anchor protein 150 (AKAP150), and phosphorylation of S845 
on the GluA1 subunit (Sanderson et al., 2016). Whilst LTD could be induced by 
NMDARs alone, the magnitude of LTD was smaller compared to when CP-AMPARs 
were expressed. Clearly then, CP-AMPARs can have a multitude of roles in normal 
physiological function of neurons. It is of interest therefore whether the molecular 
mechanisms that regulate CP-AMPARs are differentially regulated in pathological 
conditions in the brain. 
 
3. Potential role of Ca2+-permeable AMPA receptors in Alzheimer’s disease 
In an examination of postsynaptic density-rich fractions of human AD patients’ 
hippocampus, an increase in GluA1 levels was reported when compared with healthy 
control patients, whereas no changes to NMDAR subunit expression were observed 
(Marcello et al., 2012). This suggests a selective increase in GluA1-containing 
receptors at synapses in the AD hippocampus. Consistent with this, we have recently 
shown that direct infusion of oligomerised amyloid- (A) - thought to be a key driving 
force in AD pathogenesis (LaFerla et al., 2007) - into CA1 hippocampal neurons 
resulted in a rapid synaptic insertion of CP-AMPARs (Whitcomb et al., 2015).  This 
effect enhances AMPAR-mediated excitatory postsynaptic current (EPSCAMPA) and 
was absent in cells treated with IEM-1460 or in cells transfected with shRNA directed 
against the GluA1 AMPAR subunit. We also showed that these effects operate 
through PKA-mediated S845 GluA1 phosphorylation (see Figure 4) suggesting that 
A utilises a canonical mechanism of CP-AMPAR expression. In addition, a recent 
study of an AD transgenic mouse model reported aberrant CP-AMPAR expression 
and increased GluA1 phosphorylation specifically in young mice, prior to any overt 
neuropathology (Megill et al., 2015). Together, these findings indicate that CP-
AMPAR synaptic insertion may be an early-stage event in AD pathogenesis. 
 
What is currently missing in our understanding of CP-AMPAR function in AD 
pathology is how the expression of the receptor might translate into pathological 
consequences for the neuron. A compelling hypothesis is that aberrant CP-AMPAR 
expression causes excessive intracellular Ca2+ influx that leads to synaptic 
dysfunction and neurodegeneration. Physiologically, CP-AMPARs appear to be only 
transiently expressed in response to synaptic activity (Plant et al., 2006, Sutton et al., 
2006, Hou et al., 2008, Yang et al., 2010). If this is case, CP-AMPAR expression is 
tightly regulated as a physiological necessity, and this likely provides a mechanism 
that protects against aberrant and/or sustained Ca2+ flux through CP-AMPARs in 
excitatory synapses. Therefore, it is likely that aberrant activation of CP-AMPAR 
function may elicit Ca2+-mediated synaptic and neuronal degeneration. Indeed, 
alterations in Ca2+ homeostasis have been proposed to be crucial in the initial stages 
of AD development (LaFerla, 2002). Changes to Ca2+ signaling have been linked to 
dysregulation of amyloid precursor protein (APP) processing, responsible for Aβ 
production, and may augment the formation of toxic Aβ oligomers (Mattson, 1990, 
Mattson et al., 1993). Indeed, the increased production of Aβ oligomers in AD 
patients has been attributed to the higher incidence of epileptic seizures, especially in 
patients in the early stages of disease (Amatniek et al., 2006). It is also worth 
considering the overt link between CP-AMPAR expression and aberrant neuronal 
network activity that is prevalent in epilepsy (Rajasekaran et al., 2012), in the context 
of the seizure activity and cognitive impairments that are evident in APP transgenic 
mouse models and AD patients (Palop et al., 2007, Pandis and Scarmeas, 2012). 
These findings support the notion that dysregulated Ca2+ flux through sustained CP-
AMPAR expression in early phases of AD may accelerate the onset of neuronal 
network dysfunction and neuronal excitotoxicity, thus propagating cognitive decline 
(Palop and Mucke, 2009), though it remains to be seen whether CP-AMPARs are 
expressed solely at these initial stages of pathology, or again at a later point in the 
disease cycle. 
 
Aberrant synapse weakening, which promotes the elimination of synaptic 
connections, also appears to be an underlying feature of several neuropathological 
conditions (Hasbani et al., 2000, Bradley et al., 2012, Sheng et al., 2012, Park and 
Biederer, 2013). Synapse weakening processes involve a number of specific 
catalyzing signals (Collingridge et al., 2010). We have recently identified the 
activation of caspase-3 and glycogen synthase kinase 3 (GSK3β), and 
phosphorylation of the microtubule associated protein tau (pTau), as being pivotal 
and necessary end-point signals in synapse weakening (Kimura et al., 2014, Regan 
et al., 2015, Regan et al., 2016). Critically, aberrantly enhanced pTau is a common 
factor to synapse dysregulation and weakening induced by a variety of factors, 
including Aβ, stress and neurotrophins (Sotiropoulos et al., 2011, Pooler et al., 2014, 
Kailainathan et al., 2016). Given the aforementioned importance of CP-AMPAR 
expression to the initial synaptic alterations induced by stress and Aβ (Whitehead et 
al., 2013, Whitcomb et al., 2015), one favourable hypothesis is that CP-AMPAR 
expression leads to aberrant synapse weakening via the activation of signaling 
pathways culminating in tau phosphorylation. Interestingly, synaptic activity leading to 
accumulation of intracellular Ca2+ has been shown to increase phosphorylation of tau 
at serine residues 396/404 (S396/404), via Ca2+-dependent activation of GSK3β 
(Pierrot et al., 2006). In addition, hyperphosphorylation of tau has been linked to 
abnormal Ca2+ signaling through excitotoxic levels of glutamate (Guo et al., 1999, 
Leissring et al., 2000), and this dysregulated Ca2+ could serve as the conduit 
between CP-AMPAR expression and pTau. Further work is therefore required to fully 
determine the potential role of CP-AMPARs in synapse weakening pathways 
including pTau and other substrates. 
 
4. Conclusion and translation 
Neurodegenerative diseases such as AD are currently without effective treatments or 
cures (Casey et al., 2010). Given the growing evidence implicating CP-AMPARs in 
the onset of synaptic pathology (Grooms et al., 2000, Kwak and Weiss, 2006, 
Rajasekaran et al., 2012, Whitcomb et al., 2015), this form of AMPAR could well 
serve as a therapeutic target in the development of new treatments in AD and other 
neurodegenerative diseases. Indeed, targeting CP-AMPARs has been cited as a 
potential strategy in other neurological disorders (Henley and Wilkinson, 2016). 
However, in order to effectively develop novel methodologies to modulate CP-
AMPAR function in disease, we first require an understanding of the mechanisms by 
which CP-AMPARs aberrantly function, and the downstream consequences. In doing 
so, meaningful approaches in the development of CP-AMPAR regulators can be 
undertaken. Two non-competitive inhibitors of AMPA receptors, talampanel and 
perampanel, have shown some efficacy in reducing seizure activity in clinical trials 
(Chappell et al., 2002, Kerling and Kasper, 2013) and have been shown to reduce 
neuronal Ca2+ elevations in cultured neurons (Hanada et al., 2011, Paizs et al., 2011). 
However, whether these antagonists might prove to be a useful therapeutic strategy 
for AD remains to be seen. A promising strategy for limiting the progression of the 
disease could involve the development of a highly selective, bioavailable CP-AMPAR 
antagonist administered at an early, pre-symptomatic stage of AD. 
Figure Legend 
 
Figure 1. Structure and binding partners of AMPAR subunits. 
The structure of an AMPAR subunit, consisting of an extracellular N-terminal domain 
(NTD) and an intracellular C-terminal domain (CTD), three transmembrane domains 
(M1, M3, M4) and a channel pore loop (M2). The alternately spliced flip/flop site 
encodes a short amino-acid sequence within an extracellular domain of the AMPAR 
subunit and the Q/R editing site is shown within the channel pore loop. Depending on 
the AMPAR subunit, the CTD may be either short or long-tailed, which alters the 
trafficking properties and interacting partners of AMPARs. Shown are the AMPAR 
CTD binding proteins 4.1N, synapse-associated protein 97 (SAP97), post synaptic 
density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), and zonula 
occludens-1 protein (zo-1) (PDZ), N-ethylmaleimide-sensitive factor (NSF), 
Glutamate receptor-interacting protein (GRIP), and protein that interacts with protein 
C-kinase 1 (PICK1).  
 
Figure 2. The role of CP-AMPARs in synaptic function. 
(A and B) CP-AMPARs exhibit a characteristic inward rectification, a result of 
channel pore block by intracellular polyamines that limits current flow at positive 
membrane potentials. This is in contrast to GluA2-containing AMPARs, which are 
insensitive to polyamine blockade, and therefore demonstrate a linear current flow as 
a function of membrane potential. (C) The C-terminal domain (CTD) of GluA1-
containing AMPARs is subject to several characterized phosphorylation events 
through a number of identified kinases, including Ca2+/calmodulin-dependent protein 
kinase II (CaMKII), protein kinase C (PKC), protein kinase A (PKA), and p21-
activated kinase 3 (PAK3). Phosphorylation at specific residues has downstream 
effects upon synaptic AMPAR trafficking. 
 
Figure 3. Stress-primed metaplasticity and CP-AMPARs. 
Release of glucocorticoids (GCs) during an acute stressor primes synapses for 
subsequent plasticity inducing events. Transient activation of glucocorticoid receptors 
(GR) promotes CP-AMPAR insertion at the synapse via PKA-mediated 
phosphorylation of the GluA1 CTD. A consequence of this is the facilitation of LTP 
due to the addition of an NMDAR-independent, CP-AMPAR-mediated component of 
synaptic potentiation. 
 
Figure 4. Intracellular amyloid- mediated CP-AMPARs trafficking. 
Intracellular amyloid- (A) oligomers promote CP-AMPAR insertion at the synapse. 
Presynaptic glutamate release activates postsynaptic GluA2-containing AMPARs to 
elicit excitatory postsynaptic potentials (EPSCs). Infusion of A oligomers induces 
the PKA-mediated phosphorylation of S845 of GluA1, promoting the synaptic 
expression of CP-AMPARs. The consequences of this in the short-term are a rapid 
enhancement of synaptic transmission and neuronal activity. 
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